Biofrontera Inc. Files Q1 2025 10-Q

Ticker: BFRIW · Form: 10-Q · Filed: May 15, 2025 · CIK: 1858685

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

Related Tickers: BFRI

TL;DR

Biofrontera's Q1 2025 10-Q is in. Check financials.

AI Summary

Biofrontera Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 2025. Key financial data and disclosures related to its pharmaceutical preparations business are included.

Why It Matters

This filing provides investors with an update on Biofrontera's financial health and operational performance for the first quarter of 2025, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Biofrontera faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period is for the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 15, 2025.

What is Biofrontera Inc.'s Standard Industrial Classification?

Biofrontera Inc.'s SIC code is PHARMACEUTICAL PREPARATIONS [2834].

What is the company's business address?

The business address is 120 Presidential Way, Suite 330, Woburn, MA 01801.

What is the SEC file number for Biofrontera Inc.?

The SEC file number is 001-40943.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Biofrontera Inc. (BFRIW).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing